kallikrein

(redirected from Plasma kallikrein)
Also found in: Dictionary.

kallikrein

 [kal″ĭ-kre´in]
any of several serine endopeptidases that cleave kininogens to form kinins.
plasma kallikrein a hydrolytic enzyme of the plasma that cleaves HMW (high-molecular-weight) kininogen to produce bradykinin. It also activates several blood coagulation factors and plasminogen. It is formed from prekallikrein by activated coagulation factor XII.
tissue kallikrein a hydrolytic enzyme that cleaves LMW kininogen to produce kallidin. It and closely related forms are found in tissues and various glandular secretions such as lymph, pancreatic juice, urine, and saliva.

kal·li·kre·in

(kal'i-krē'in),
A group of enzymes (for example, plasma, tissue, pancreatic, urinary, or submandibular kallikrein) that converts kininogen by proteolysis to bradykinin or kallidin. Trypsin and plasmin can also effect the conversion. Plasma kallikrein activates factor XII and acts on kininogen. Tissue kallikrein is a serine endopeptidase that can generate kallidin from kininogen.

kallikrein

/kal·li·kre·in/ (kal″ĭ-kre´in) any of several serine proteinases that cleave kininogens to form kinins.
plasma kallikrein  a plasma hydrolase that cleaves HMW kininogen to produce bradykinin and also activates blood coagulation factors XII and VII and plasminogen.
tissue kallikrein  a hydrolase of tissues and various glandular secretions that cleaves LMW kininogen to form kallidin.

KLK4

A gene on chromosome 19q13.41 that encodes a serine protease expressed in the prostate.

Molecular pathology
Mutations of KLK4 cause amelogenesis imperfecta hypomaturation type 2A1.

kal·li·kre·in

(kal'i-krē'in)
A group of enzymes (e.g., plasma, tissue, pancreatic, urinary, submandibular kallikrein) that can convert kininogen by proteolysis to bradykinin or kallidin; trypsin and plasmin can also effect the conversion; plasma kallikrein activates the Hageman factor and acts on kininogen. Tissue kallikrein is a serine endopeptidase that can generate kallidin from kininogen.
Synonym(s): kininogenase, kininogenin.

Kallikrein

Any of a group of compounds in the body known as serine endopeptidases that help to break down proteins into smaller units. Prostate-specific antigen belongs to this group of chemicals. A recently discovered kallikrein may be useful as a biomarker for ovarian cancer.
Mentioned in: Ovarian Cancer

kal·li·kre·in

(kal'i-krē'in)
A group of enzymes that can convert kininogen by proteolysis to bradykinin or kallidin.

kallikrein

(kal´ikrē´in),
n a group of enzymes (plasma, tissue, pancreatic, urinary, submandibular kallikrein) that can convert kininogen to bradykinin or kallidin; trypsin and plasmin can also affect the conversion.
kallikrein-kinin system,
n a proposed hormonal system that functions within the kidney, with the en-zyme kallikrein in the re-nal cortex mediating production of bradykinin, which acts as a vasodilator peptide.

kallikrein

any of a group of proteolytic enzymes present in various glands, lymph, urine, blood plasma, etc., or produced directly from mast cells or basophils, or indirectly from activated platelets. The major action of kallikreins is the liberation of kinins from α-2-globulins (kininogens), and they hence have vasodilator and whealing actions.

kallikrein-kinin system
the enzyme system responsible for capillary permeability and smooth muscle contraction.
References in periodicals archive ?
KVD900 is the second clinical candidate from a portfolio of oral plasma kallikrein inhibitors for potential treatment of HAE.
Plasma kallikrein participates in the surface-dependent activation of blood coagulation, fibrinolysis, kinin generation, and inflammation.
NASDAQ:DYAX) today announced results from a preclinical study of DX-2930, their internally developed, fully human monoclonal antibody inhibitor of plasma kallikrein, at the 2013 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting which is taking place February 22-26, 2013 in San Antonio, TX.
Work in the Feener lab had previously implicated plasma kallikrein in diabetic eye complications.
Because of the extreme susceptibility of ITIH4 to plasma kallikrein and the partial homology of the amino acid sequence to that of bradykinin released from high-molecular-mass kininogen by plasma kallikrein, human ITIH4 had been proposed to be a potential precursor of bioactive peptides (1, 2).
M2 EQUITYBITES-April 20, 2017-ThromboGenics advances pre-clinical development of novel plasma kallikrein inhibitor THR-149 to treat DME
Dyax is a publicly traded, Massachusetts-based biotechnology company primarily focused on the development of plasma kallikrein inhibitors for the treatment of HAE, a debilitating and sometimes life-threatening rare genetic disease.
A publicly traded, Massachusetts-based biotechnology firm, Dyax is mainly focused on the development of plasma kallikrein (pKal) inhibitors for the treatment of HAE, a debilitating and sometimes life-threatening rare genetic disease.
The investigational agent BCX4161 is a potent oral inhibitor of plasma kallikrein, which plays a key role in hereditary angioedema (HAE) by inducing vasodilation, edema, and nonvascular smooth muscle contraction.
These peptides might be generated by action of proteases such as thrombin and plasma kallikrein (Table 1).
M2 PHARMA-April 20, 2017-ThromboGenics advances pre-clinical development of novel plasma kallikrein inhibitor THR-149 to treat DME
BCX7353 is a novel, once-daily, selective inhibitor of plasma kallikrein in development for the prevention of angioedema attacks in patients diagnosed with HAE.